The FDA has approved an Alzheimer’s drug that slowed the rate of cognitive decline in clinical trials without using an advisory committee. The high drug cost — priced at $26,000 per year, Eisai said — combined with strict restrictions on reimbursement by US government-funded health schemes will severely limit the number of patients able to access the medicine, at least for now. What is going on here?

Healthcare is the problem of our country, and if we don’t fix it, it will break the bank, our health, or both. It deserves the world’s best and brightest minds working on fixing it. But how we go about fixing healthcare matters. The strategic common denominator across big tech ventures into healthcare is that they are not primarily solving what healthcare needs. They are mainly solving how to make money with their respective core business, not helping customers.

Researchers aimed to test the feasibility of a DTx program for patients with cancer, as measured by engagement, retention, and acceptability. In addition, we explored the effects of the program on cancer-related QoL. The high retention, employment, and acceptability found in this study demonstrated that multidisciplinary DTx is feasible for patients with cancer.

Research has shown that 74% of all U.S. adults use the Internet, and 61% have looked for health or medical information on the Internet. Additionally, 49% have accessed a website that provides information about a specific medical condition or problem. Many people get health information from the Internet but are left on their own to determine if it’s credible. This is one area where pharma companies can restore trust and excel.